These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 29235045)

  • 1. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Han SN; Amant F; Cardonick EH; Loibl S; Peccatori FA; Gheysens O; Sangalli CA; Nekljudova V; Steffensen KD; Mhallem Gziri M; Schröder CP; Lok CAR; Verest A; Neven P; Smeets A; Pruneri G; Cremonesi M; Gentilini O;
    Breast Cancer Res Treat; 2018 Apr; 168(2):551-557. PubMed ID: 29235045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of axillary nodal metastases on lymphatic mapping and sentinel lymph node identification rate in patients with early stage breast cancer.
    Pelosi E; Ala A; Bellò M; Douroukas A; Migliaretti G; Berardengo E; Varetto T; Bussone R; Bisi G
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):937-42. PubMed ID: 15838690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years.
    Groetelaers RP; van Berlo CL; Nijhuis PH; Schapers RF; Gerritsen HA
    Eur J Surg Oncol; 2009 Feb; 35(2):159-63. PubMed ID: 18789841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dye- and gamma probe-guided sentinel lymph node biopsy in breast cancer patients: using patent blue dye and technetium-99m-labeled human serum albumin.
    Tsugawa K; Noguchi M; Miwa K; Bando E; Yokoyama K; Nakajima K; Michigishi T; Tonami N; Minato H; Nonomura A
    Breast Cancer; 2000 Jan; 7(1):87-94. PubMed ID: 11029778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.
    Albo D; Ames FC; Hunt KK; Ross MI; Singletary SE; Kuerer HM
    Breast Cancer Res Treat; 2003 Jan; 77(1):9-14. PubMed ID: 12602900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of the lymphoscintigraphy in the evaluation of non-axillary sentinel lymph node localization in breast cancer.
    Gherghe M; Bordea C; Blidaru A
    Chirurgia (Bucur); 2015; 110(1):26-32. PubMed ID: 25800312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.
    Tokmak H; Kaban K; Muslumanoglu M; Demirel M; Aktan S
    World J Surg Oncol; 2014 Jul; 12():205. PubMed ID: 25016393
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang J; Fan T; He Y; Chen X; Fan Z; Xie Y; Wang T; Li J; Ouyang T
    Breast Cancer Res Treat; 2018 Apr; 168(2):365-370. PubMed ID: 29209873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
    Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
    Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Nonsentinel Lymph Node Metastasis in Breast Cancer: A Multicenter Retrospective Study.
    Mikami Y; Yamada A; Suzuki C; Adachi S; Harada F; Yamamoto S; Shimada K; Sugae S; Narui K; Chishima T; Ishikawa T; Ichikawa Y; Endo I
    J Surg Res; 2021 Aug; 264():45-50. PubMed ID: 33752166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.